Investing News Network

投资新闻网

January 13, 2025

2025年1月13日

Sona Nanotech

索纳纳米技术

Inc. (

公司(

CSE: SONA

CSE:SONA

) (OTCQB: SNANF) (the 'Company', 'Sona') is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology. This research article includes new follow-up data which provides a comprehensive analysis of the immunity activated by Sona's Targeted Hyperthermia Therapy ('THT').

)（OTCQB:SNANF）（“公司”，“Sona”）很高兴地宣布，我们之前宣布的临床前乳腺癌和黑色素瘤疗效研究的最新完整发现已发表在同行评审的科学期刊《免疫学前沿》上。这篇研究文章包括新的随访数据，该数据全面分析了Sona靶向热疗（“THT”）激活的免疫力。

The published manuscript titled, 'Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically 'Cold' Tumors' is available online in electronic form (here) and will be in print in its upcoming issue of Frontiers in Immunology - Cancer Immunology and Immunotherapy.

已发表的题为“具有独特生物相容性的金纳米棒的靶向肿瘤内热疗在两种免疫原性“冷”肿瘤中诱导强烈的免疫原性细胞死亡”的手稿以电子形式在线提供（此处），并将在即将出版的《免疫学前沿-癌症免疫学和免疫疗法》中发表。

Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology..

《免疫学前沿》是该领域的领先期刊，在基础免疫学、转化免疫学和临床免疫学领域发表了严格的同行评审研究。。

Sona's proprietary, innovative technology uses the Company's patented, biocompatible gold nanorods ('GNRs') to deliver precision, targeted, non-destructive hyperthermia therapy directly to cancers, thereby alleviating the systemic toxicity associated with most other cancer therapies. In this study, Sona's team confirmed that its therapy causes cancer-specific cell death that activates a strong immune response by the body's immune system.

Sona的专有创新技术使用该公司获得专利的生物相容性金纳米棒（“GNR”）直接为癌症提供精确，有针对性的非破坏性热疗，从而减轻与大多数其他癌症治疗相关的全身毒性。在这项研究中，索纳的团队证实，其疗法会导致癌症特异性细胞死亡，从而激活人体免疫系统的强烈免疫反应。

Of critical importance in Sona's publication is the evidence that the 'novel immunity' generated by Sona's THT is observed in cancers that are known to be completely resistant to modern immunotherapies. .

在Sona的出版物中至关重要的是，有证据表明，在已知对现代免疫疗法完全耐药的癌症中观察到了由Sona的THT产生的“新型免疫力”。

Sona's Chief Medical Officer, and the manuscript's senior author, Dr. Carman Giacomantonio, commented, '

Sona的首席医疗官和手稿的资深作者Carman Giacomantonio博士评论道

I am extremely proud of my research team lead by Dr. Barry Kennedy, and the quality of the research we have produced. To be published in such a highly respected and rigorously peer-reviewed journal as Frontiers in Immunology is no small feat!

我为我由巴里·肯尼迪博士领导的研究团队以及我们所做研究的质量感到无比骄傲。能在如此受人尊敬且经过严格同行评审的期刊上发表《免疫学前沿》是一项不小的壮举！

In our studies, we've shown in industry standard, pre-clinical cancer models that Sona's therapy can eliminate cancers by converting them from 'cold', immune unresponsive tumors, into 'hot' immunogenic tumors. In the many years I have been involved in cancer research and treatment, I have never seen a treatment trigger such a powerful immune response in otherwise 'cold' tumors and our data makes it clear that there was no meaningful immune response to standard immunotherapies without THT in these studies.

在我们的研究中，我们已经在行业标准的临床前癌症模型中表明，Sona的疗法可以通过将癌症从“冷的”，免疫无反应的肿瘤转化为“热的”免疫原性肿瘤来消除癌症。在我参与癌症研究和治疗的多年中，我从未见过一种治疗方法在其他“冷”肿瘤中引发如此强大的免疫反应，我们的数据表明，在这些研究中，没有THT的标准免疫疗法没有有意义的免疫反应。

Our publication in Frontiers in Immunology elevates our findings to an international level, giving us new audience with other leading cancer research laboratories and potential industry partners. Most importantly, this publication provides us with 'proof-of-concept', supporting the clinical trial protocols we are striving to launch in 2025.' .

我们在《免疫学前沿》上的出版物将我们的研究结果提升到了国际水平，为我们提供了其他领先癌症研究实验室和潜在行业合作伙伴的新受众。最重要的是，本出版物为我们提供了“概念验证”，支持我们力争在2025年推出的临床试验方案。

'

'

Our research appearing in a leading scientific journal is evidence of Sona delivering on our commitment to build a 'mountain of data' that will support our planned regulatory filings. Its findings motivate our team to press on, affirming our conviction that THT- immunotherapy will be highly effective in the clinical setting.

我们的研究发表在一家领先的科学期刊上，证明了Sona履行了我们建立“数据山”的承诺，这将支持我们计划的监管备案。它的发现激励我们的团队继续努力，证实了我们的信念，即THT免疫疗法在临床环境中将非常有效。

While we continue to conduct research on other cancers, we are now also focused on delivering evidence through first-in-human clinical trials, both here and abroad, as quickly as possible. This peer-reviewed publication of successful treatment using Sona's THT in melanoma and breast cancers provides the credibility necessary to help make that happen,.

在我们继续对其他癌症进行研究的同时，我们现在也致力于通过国内外首次人体临床试验尽快提供证据。这篇同行评议的出版物成功地使用了Sona的THT治疗黑色素瘤和乳腺癌，为实现这一目标提供了必要的可信度，。

' said David Regan, Chief Executive Office of

'首席执行官DavidRegan说

Sona Nanotech

索纳纳米技术

.

.

Contact:

联系人：

David Regan, CEO

David Regan，首席执行官

+1-902-442-0653

+1-902-442-0653

david@sonanano.com

david@sonanano.com

About

关于

Sona Nanotech

索纳纳米技术

Inc.

公司。

Sona Nanotech

索纳纳米技术

is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively.

正在开发靶向热疗™，一种光热癌症疗法，它使用治疗热来治疗实体癌肿瘤。热量通过红外光传递给肿瘤，红外光被肿瘤中Sona的金纳米棒吸收，并作为热量重新释放。治疗热（42-48°C）刺激免疫系统，缩小肿瘤，灭活癌症干细胞，增加肿瘤灌注-从而使药物更有效地到达所有肿瘤区室。

Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. .

靶向热疗有望安全，有效，微创，成本具有竞争力，并且是药物治疗和其他癌症治疗的有价值的辅助手段。

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms.

Sona开发了多种专有的金纳米颗粒制造方法，用于开发癌症治疗和诊断测试平台。

Sona Nanotech

索纳纳米技术

's gold nanorod particles are cetyltrimethylammonium ('CTAB') free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

的金纳米棒颗粒不含十六烷基三甲基铵（“CTAB”），消除了在医疗应用中使用其他金纳米棒技术的毒性风险。

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain 'forward-looking statements' under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona's preclinical and clinical study plans.

关于前瞻性信息的警告声明：本新闻稿包括适用的加拿大证券立法下的某些“前瞻性声明”，包括关于靶向热疗的预期应用和潜在机会的声明，以及Sona的临床前和临床研究计划。

Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated.

前瞻性陈述必然基于一些假设或估计，这些假设或估计虽然被认为是合理的，但受到已知和未知风险、不确定性和其他因素的影响，这些因素可能导致实际结果和未来事件与此类前瞻性陈述所明示或暗示的结果和未来事件存在重大差异，包括Sona可能无法成功获得足够的临床和其他数据以提交监管报告，筹集足够的额外资本，获得专利或开发预期治疗的风险，以及THT可能无法证明具有目前预期的益处的风险。

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

由于实际结果和未来事件可能与此类声明中预期的结果和事件存在重大差异，因此无法保证此类声明将被证明是准确的。。除非法律要求，否则Sona不打算或有义务更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。

.

.

Not for distribution to United States newswire services or for dissemination in the United States

不得分发给美国新闻通讯社或在美国传播

To view the source version of this press release, please visit

要查看此新闻稿的源版本，请访问

https://www.newsfilecorp.com/release/236960

https://www.newsfilecorp.com/release/236960

News Provided by Newsfile via QuoteMedia

新闻文件通过QuoteMedia提供的新闻

Sona Nanotech

索纳纳米技术

SONA:CNX

美国有线电视新闻网

CSE:SONA

CSE:SONA

Emerging Tech Investing

新兴技术投资

SONA:CNX

美国有线电视新闻网